1. Clinical & Scientific Overview
Diethylcarbamazine Citrate (DEC) (TIP-MED-000345, Reference Code [8.32]-C75) is classified under
Antimicrobials — Antimalarial & Anthelmintic Agents (Ch 08) as a Avermectin Glutamate-Gated Chloride Channel Agonist & Piperazine Antifilarial (Schedule H | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [8.32] (Ivermectin & Diethylcarbamazine Citrate (DEC)). Representative Indian Market Examples (Edition 2.7 Ch 08 [8.32], p. 108): Ivermectin: Ivecop (Menarini), Iverkem (Alkem), Vermact (Mankind); FDC: Bandy-Plus (Albendazole 400 mg + Ivermectin 6/12 mg). DEC: Hetrazan (Pfizer), Banocide / Banocide Forte (GSK) — Strengths & Dosage Forms: Ivermectin Tablets (Dispersible/Uncoated): 3 mg, 6 mg, 12 mg; Topical Cream: 1%. DEC Tablets: 50 mg, 100 mg; Syrup: 50 mg/5 mL, 120 mg/5 mL
Ivermectin Tablets (Dispersible/Uncoated): 3 mg, 6 mg, 12 mg; Topical Cream: 1%. DEC Tablets: 50 mg, 100 mg; Syrup: 50 mg/5 mL, 120 mg/5 mL
3. Mechanism of Action & Pharmacodynamics
Avermectin Glutamate-Gated Chloride Channel Agonist & Piperazine Antifilarial (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Antimicrobials — Antimalarial & Anthelmintic Agents (Ch 08): clinical efficacy is mediated via Avermectin Glutamate-Gated Chloride Channel Agonist & Piperazine Antifilarial (Schedule H | NLEM 2022) for Ivermectin: Strongyloidiasis, crusted/refractory scabies (200 mcg/kg PO on Day 1 & Day 8–14 alongside topical Permethrin 5%), pediculosis capitis, cutaneous larva migrans. DEC: Lymphatic filariasis (Wuchereria bancrofti) and Tropical Pulmonary Eosinophilia (TPE — very common in India!).
4. Therapeutic Indications & Evidence-Supported Uses
- Ivermectin: Strongyloidiasis, crusted/refractory scabies (200 mcg/kg PO on Day 1 & Day 8–14 alongside topical Permethrin 5%), pediculosis capitis, cutaneous larva migrans
- DEC: Lymphatic filariasis (Wuchereria bancrofti) and Tropical Pulmonary Eosinophilia (TPE — very common in India!)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Ivermectin (Scabies / Strongyloidiasis): 200 mcg/kg PO as a single dose (typically 12 mg for a 60 kg adult); for Scabies, MUST repeat a second 200 mcg/kg dose on Day 8–14 (Ivermectin is NOT ovicidal!). DEC: Filariasis: 6 mg/kg/day in 3 divided doses (100 mg TDS) for 12 days; TPE: 6 mg/kg/day in 3 divided doses for 14–21 days
Administration & Meal Timing: Take Oral Ivermectin on an empty stomach with water. Take DEC immediately AFTER meals to minimise nausea | Ivermectin: Single dose on Day 1 & Day 8–14. DEC: Morning, Afternoon & Night (TDS) after meals
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [8.32].
Renal: Reduce DEC dose in moderate-to-severe CKD. Hepatic: Caution with Ivermectin in severe liver disease
Renal: Reduce DEC dose in moderate-to-severe CKD. Hepatic: Caution with Ivermectin in severe liver disease
Renal: Reduce DEC dose in moderate-to-severe CKD. Hepatic: Caution with Ivermectin in severe liver disease
7. Contraindications, Precautions & High-Risk Warnings
- Ivermectin CONTRAINDICATED in children <15 kg (or <5 years — immature BBB allows GABA neurotoxicity!), pregnancy, and Loa loa co-infection. DEC CONTRAINDICATED in Onchocerciasis
Key Clinical Precautions: Renal: Reduce DEC dose in moderate-to-severe CKD. Hepatic: Caution with Ivermectin in severe liver disease
8. Adverse Effects Profile
- Ivermectin: Transient exacerbation of pruritus in first 24–48h as mites die, mild dizziness, nausea. DEC: Fever, headache, myalgia, anorexia, arthralgia (immunological reaction to dying microfilariae in first 2–3 days — treat with Paracetamol & Antihistamines, do not stop DEC!)
- Neurotoxicity/encephalopathy, ataxia, coma (in Ivermectin overdose, children <15 kg, or P-gp inhibitor co-administration)
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Strong P-gp inhibitors (Itraconazole, Ketoconazole, Cyclosporine, Verapamil) may increase CNS penetration of Ivermectin; monitor Warfarin INR
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [8.32].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: FOR SCABIES: Take the second Ivermectin tablet 7–14 days after the first tablet (to kill newly hatched mites), treat all household contacts simultaneously, and note that itching may persist for 1–2 weeks after mites are dead (use calamine/antihistamine, do not keep repeating Ivermectin daily!); FOR BANOCIDE/HETRAZAN: take after meals
- Meal & Clock Timing Instruction: Take Oral Ivermectin on an empty stomach with water. Take DEC immediately AFTER meals to minimise nausea (Ivermectin: Single dose on Day 1 & Day 8–14. DEC: Morning, Afternoon & Night (TDS) after meals)
- Missed Dose Protocol: Take DEC after next meal if missed; do not miss Day-8 repeat dose of Ivermectin in scabies
- Geriatric Dispensing Pearl: Oral Ivermectin (200 mcg/kg Day 1 & Day 8) + Topical Permethrin 5% is highly effective for institutional/elderly crusted scabies
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Ivermectin Tablets (Dispersible/Uncoated): 3 mg, 6 mg, 12 mg; Topical Cream: 1%. DEC Tablets: 50 mg, 100 mg; Syrup: 50 mg/5 mL, 120 mg/5 mL
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.31] Albendazole & Mebendazole — Benzimidazole Beta-Tubulin Polymerisation Inhibitor Anthelmintics
- [8.32] Ivermectin & Diethylcarbamazine Citrate (DEC) — Avermectin Glutamate-Gated Chloride Channel Agonist & Piperazine
- [8.29]-C72 Primaquine Phosphate — 4-Aminoquinoline Blood Schizonticide & 8-Aminoquinoline Hypnozoit
- [8.30]-C73 Artesunate — Artemisinin-Based Combination Therapy (ACT-AL) & Parenteral Sever